Shanghai Innostar Bio-Tech Co., Ltd. (688710.SH) announced that its wholly-owned subsidiary, Innostar Bio-Tech Nantong Co., Ltd., has successfully passed a GLP inspection by the National Medical Products Administration for its "Expansion Project of the High-Quality Non-Clinical Innovative Drug Comprehensive Evaluation Platform." The subsidiary has received the "Drug GLP Certification Certificate" issued by the NMPA.